RDNT RadNet, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 790526 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.1%
TTM net income YoY-76.1%
TTM EPS YoY-81.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin3.1%
Net margin-0.9%
FCF margin—
EBITDA margin10.6%
Returns
ROE-2.1%
ROA-0.6%
ROIC (approx.)2.8%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets66.4%
Debt / equity1.18x
Current ratio1.49x
Interest coverage0.99x
Cash quality & payout
Operating cash flow / net income-15.54x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.04B | $1.83B |
| Operating income | $61.99M | $104.62M |
| Interest expense | $69.91M | $79.85M |
| Pretax income | $31.91M | $44.86M |
| Income tax | $14.86M | $6.03M |
| Net income | -$18.65M | $2.79M |
| EBITDA | $214.12M | $242.46M |
| EPS (basic) | -0.25 | 0.04 |
| EPS (diluted) | -0.25 | 0.04 |
| Weighted avg. shares (diluted) | 75.19M | 74.76M |
| Balance sheet | ||
| Cash & equivalents | $767.22M | $740.02M |
| Receivables | $200.32M | $185.82M |
| Current assets | $1.03B | $1.02B |
| PP&E, net | $807.70M | $694.79M |
| Goodwill | $907.66M | $710.66M |
| Intangibles | $148.51M | $81.35M |
| Total assets | $3.76B | $3.29B |
| Current liabilities | $586.76M | $479.71M |
| Short-term debt | $25.42M | $24.69M |
| Long-term debt | $1.06B | $991.57M |
| Total debt | $1.09B | $1.02B |
| Total liabilities | $2.40B | $2.15B |
| Shareholders' equity | $1.09B | $902.31M |
| Net debt | $322.70M | $276.25M |
| Shares outstanding | 77.40M | 74.04M |
| Cash flow statement | ||
| Operating cash flow | $298.82M | $233.02M |
| Investing cash flow | -$343.87M | -$233.07M |
| Financing cash flow | $72.21M | $397.95M |
| Depreciation & amortization | $152.13M | $137.84M |
| Stock-based compensation | $54.60M | $29.83M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.